STOCKHOLM, May 24, 2024 /PRNewswire/ -- A pioneering
study, presented today at the 61st ERA Congress, has
demonstrated that semaglutide significantly reduces the risk of
major kidney disease events, cardiovascular outcomes, and all-cause
mortality in patients with type 2 diabetes and chronic kidney
disease.
The FLOW (Evaluate Renal Function with Semaglutide
Once Weekly) study is a double-blind, randomised,
placebo-controlled international trial comprising 3,533 patients,
with a median follow-up period of 3.4 years. The trial was designed
to assess the efficacy and safety of semaglutide, a once-weekly
subcutaneous glucagon-like peptide 1 (GLP-1) receptor agonist, in
preventing major kidney outcomes, specifically kidney failure,
substantial loss of kidney function, and death from kidney or
cardiovascular causes, in individuals with type 2 diabetes and
chronic kidney disease. Patients either received semaglutide 1.0 mg
once weekly or placebo.
Participants who received semaglutide had a 24% risk reduction
for the composite primary endpoint, including kidney outcomes and
death due to cardiovascular and kidney causes, compared to
those who received placebo. This reduction risk was consistent
across both kidney-specific and cardiovascular death outcomes.
Secondary endpoints also showed significant improvements with
semaglutide. The total eGFR slope was 1.16 ml/min/1.73m2/year
slower, the risk of major cardiovascular events was decreased by
18%, and the risk of all-cause mortality was reduced by 20%.
Professor Vlado Perkovic
commented, "The use of semaglutide in people with type 2 diabetes
and chronic kidney disease can lower the risk of major kidney
outcomes and reduce the risk of cardiovascular events,
cardiovascular death and all-cause death. These benefits signify a
profound clinical impact saving kidneys, hearts and lives, for
patients with type 2 diabetes and chronic kidney disease.
Additionally, the reassuring safety findings further support the
strong potential value of semaglutide in this population."
Chronic kidney disease affects over 800 million people worldwide
and is particularly prevalent among individuals with type 2
diabetes. Chronic kidney disease poses a significant risk of kidney
failure, cardiovascular events and death, highlighting the critical
need for research into its prevention and treatment.
The FLOW trial was overseen by an academic-led Steering
Committee, in partnership with the study sponsor, Novo Nordisk,
which also managed trial operations. The study is being published
today in the New England Journal of Medicine and presented at the
61st ERA Congress in Stockholm,
Sweden.
View original
content:https://www.prnewswire.co.uk/news-releases/61st-era-congress-semaglutide-significantly-reduces-risk-of-major-kidney-disease-events-cardiovascular-outcomes-and-mortality-in-patients-with-type-2-diabetes-and-chronic-kidney-disease-groundbreaking-study-reveals-302152722.html